\n<\/p>\n
Eli Lilly (NYSE: LLY) has been a leader in the weight management sector, but it faced challenges, particularly with inconsistent insurance coverage for its anti-obesity drug, Zepbound. Improving this coverage could significantly enhance sales for the already popular medication. Recently, good news from CVS Health (NYSE: CVS) has brought new hope.<\/p>\n
On May 28, CVS Caremark, part of CVS Health, announced that it will start covering Zepbound from October 1. This is a crucial update since CVS had previously taken this medication off its coverage list. Additionally, CVS will start covering Eli Lilly\u2019s new GLP-1 pill, Foundayo, beginning June 1.<\/p>\n
These changes are expected to help Eli Lilly compete more effectively with its main rival, Novo Nordisk, which already has its weight loss medications covered by CVS Caremark. With the news, three of the largest pharmacy benefit managers (PBMs) in the U.S. will now cover both Zepbound and Foundayo. Access to these treatments at affordable prices will be easier for more patients, allowing Eli Lilly to tackle competition from telemedicine companies offering lower-cost alternatives to Zepbound.<\/p>\n
Can Eli Lilly sustain its momentum in the weight loss market over the next few years despite growing competition? Yes, it seems likely. The company\u2019s advancements in coverage and the early success of Foundayo\u2014approved only in April\u2014show that the anti-obesity market still has plenty of room for growth. A significant portion of Foundayo\u2019s users had never used GLP-1 medications before, perhaps due to their dislike for injections.<\/p>\n
Eli Lilly has a diverse product range that meets the needs of many potential customers who currently are not using these treatments. Meanwhile, Eli Lilly is outperforming its peers, as its revenues and earnings grow at a faster rate. In the first quarter, the company reported a 56% year-over-year increase in sales, reaching $19.8 billion, while adjusted earnings per share surged to $8.55, marking a 156% jump from the previous year.<\/p>\n
Additionally, Eli Lilly boasts a strong lineup of future products beyond just diabetes and weight loss drugs. In the next five years, the company plans to launch several new medications, which should help boost sales further. While some investors believe that Eli Lilly\u2019s stock is quite pricey\u2014trading at 29.3 times its expected earnings compared to an average of 16.9 times for healthcare stocks\u2014the company’s impressive performance justifies this premium.<\/p>\n
Before deciding to invest in Eli Lilly, here are some considerations:<\/p>\n
While the analysts from the Motley Fool Stock Advisor have identified their top ten stock picks for investors, Eli Lilly was not included. The selected stocks are anticipated to yield significant returns in the coming years.<\/p>\n
Experienced investors know that past recommendations have proven fruitful. For example, had you invested $1,000 in Netflix when it made the list on December 17, 2004, you\u2019d have over $439,000 today!<\/p>\n
The Motley Fool’s Stock Advisor boasts an average return of 959%, far exceeding the 210% return of the S&P 500. Don\u2019t miss the chance to see their latest top ten stock picks and join a community of investors focused on mutual growth.<\/p>\n
For further insights.<\/p>\n\n","protected":false},"excerpt":{"rendered":"
Key Points CVS Caremark will begin covering Eli Lilly\u2019s weight loss medications. This decision could potentially increase Eli Lilly’s sales. Eli Lilly continues to look promising even now. Eli Lilly (NYSE: LLY) has been a leader in the weight management sector, but it faced challenges, particularly with inconsistent insurance coverage for its anti-obesity drug, Zepbound.<\/p>\n","protected":false},"author":1,"featured_media":33763,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_lock_modified_date":false,"footnotes":""},"categories":[32],"tags":[22235,8052,23599],"class_list":["post-33762","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-cvs-caremark","tag-cvs-health","tag-eli-lilly"],"_links":{"self":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/33762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/comments?post=33762"}],"version-history":[{"count":0,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/33762\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media\/33763"}],"wp:attachment":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media?parent=33762"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/categories?post=33762"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/tags?post=33762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}